ABSTRACT
Ovarian cancer is the most lethal of gynecological cancers. It presents with clinical symptoms usually at an advanced stage, when intervention and treatment are unsatisfactory. Patients usually die of uncontrolled locoregional intraperitoneal spread and complications. The identification of a gene linked with ovarian/breast cancer families and the powerful polymerase chain reaction screening technique, may provide means of identifying a population where routine screening may bear dividends. The murine models, however, that are of most interest to the ovarian cancer circumstances are primarily those that deal with the synchronous regional and systemic administration of antibody, either for therapy or localization. Models of intraperitoneal tumors have been created using human cell lines from ovarian or other cancers. Tumor xenografts implanted subcutaneously have often been used as radioimmunotherapy targets with consistent results, the justification is that if this model does not work then there is no reason to advance to the human study.
